This market resolves to Yes if the Endocrine Society publicly announces, by September 2026, that hormone therapy is recommended over non-hormonal treatments (including fezolinetant) for menopause based on official guidelines or recommendations. The announcement must clearly state preference and be available on the Endocrine Society's official communication channels.